Drugs / Opnurasib
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05329623 | May 2022 → Apr 2024 | small cell lung carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07468071 | Jun 2026 → Jun 2029 expected | — | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05358249 | Oct 2022 → Sep 2026 overdue | colorectal carcinoma, non-small cell lung carcinoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04699188 | Feb 2021 → Jan 2027 expected | colorectal carcinoma, non-small cell lung carcinoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05999357 | Apr 2024 → Aug 2027 | metastatic malignant neoplasm in the brain, non-small cell lung carcinoma | Maastricht University Medical Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT05714891 | Sep 2023 → Aug 2026 overdue | non-small cell lung carcinoma | Canadian Cancer Trials Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05445843 | Dec 2022 → Nov 2024 overdue | respiratory system cancer | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05132075 | Jun 2022 → Sep 2026 overdue | non-small cell lung carcinoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-04-26 | Novartis Pharmaceuticals | Results Novartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook novartis.com ↗
JDQ443 (KRAS G12C inhibitor) demonstrated anti-tumor activity with acceptable safety in NSCLC (April) |
| 2022-04-11 | Novartis Pharmaceuticals | Results Novartis announces early clinical data for unique KRASG12C inhibitor at American Association for Cancer Research annual meeting novartis.com ↗
JDQ443, an investigational selective, covalent, and orally bioavailable KRAS G12C inhibitor, shows 57% confirmed ORR at recommended dose of 200 mg twice daily in Phase Ib study in patients with advanced non-small cell lung cancer (NSCLC) |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-04-26 | Novartis Pharmaceuticals | Novartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook novartis.com ↗ |
| 2022-04-11 | Novartis Pharmaceuticals | Novartis announces early clinical data for unique KRASG12C inhibitor at American Association for Cancer Research annual meeting novartis.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Opnurasib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07468071 ↗ |
| Known as | JDQ443 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05329623 ↗ |
| Known as | Nvp-jdq-443 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5077861 ↗ |
| Action | Inhibit | “JDQ443 is an investigational covalent KRASG12C inhibitor derived from structure-based drug design followed by extensive optimization of two dissimilar prototypes.” PMID 36399068 ↗ Nov 2022 |
| Modality | Small molecule | “JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRAS(G12C)” PMID 36399068 ↗ Nov 2022 |
| Route | Oral | “orally administered” NCT05132075 ↗ |
| Target | KRAS | “JDQ443 is an investigational covalent KRASG12C inhibitor derived from structure-based drug design followed by extensive optimization of two dissimilar prototypes.” PMID 36399068 ↗ Nov 2022 |